333D Ltd Reports 69% Revenue Growth and Advances AI Clinical Software
333D Ltd (ASX:T3D) posted a 69% increase in FY2026 cash receipts to $1.7 million, completing its software development program and investing in AI infrastructure, positioning itself at the intersection of applied AI and healthcare digital assets.
- 69% increase in FY2026 cash receipts to $1.7 million
- Completion of FY2026 software development program
- Investment in AI data centre platform Firmus Grid
- Net operating cash outflow of $250,085 in June quarter
- Bitcoin holdings valued at $185,530 augment liquidity
Strong Revenue Growth Amid Elevated Development Costs
333D Ltd (ASX:T3D) reported a substantial 69% jump in cash receipts from customers for FY2026, reaching $1.7 million compared to $1 million the previous year. This surge was driven by increased delivery of software development and digital asset management services to healthcare sector clients. However, the June 2026 quarter saw a net operating cash outflow of $250,085, a reversal from the prior quarter's positive cash flow, largely reflecting the completion phase of the company's FY2026 software development program and associated corporate costs.
Advancing AI Clinical Software for Dental Imaging
Central to 333D’s strategy is its proprietary AI clinical software built on DICOM digital assets. The company reached a major milestone in model training and evaluation using a multi-thousand-study dataset of de-identified cone-beam CT scans, sourced through a data-sharing agreement established in 2024. This software targets the dental and maxillofacial imaging market, with commercialisation pathways including clinical-network integration and standalone offerings. The development remains in progress, with optimisation and validation activities underway.
Expanding AI-Enabled Platform and Strategic AI Infrastructure Investment
333D also bolstered its AI-enabled digital asset management platform by deploying $95,800 in capital equipment to enhance processing capacity, supporting higher volumes of automated encoding and classification of medical imaging and 3D data. Complementing this, the company invested $149,930 in Firmus Grid Limited, an AI data centre platform backed by NVIDIA and Coatue Management. This minority equity stake offers 333D shareholders exposure to next-generation Australian AI infrastructure, aligning with its broader AI strategy.
Liquidity Position Supported by Bitcoin Treasury and Capital Reserves
At quarter-end, 333D held $312,018 in cash and Bitcoin valued at $185,530, collectively providing nearly $500,000 in liquidity. The Bitcoin holdings remain a strategic long-term asset but are liquid and could be realised if necessary to support working capital. The company also retains capacity to raise equity capital under ASX Listing Rules and has a history of successful capital raises, including a $1 million placement in September 2025.
Governance Update and Forward Funding Strategy
The company announced a leadership change with Ms Alyn Tai appointed as Company Secretary, bringing extensive governance and ASX-listed company experience. On funding, 333D expects its net operating cash flows to improve in FY2027 as software development expenditure normalises post-program completion. The Board anticipates a significant R&D tax incentive refund for FY2026 and retains flexibility to moderate discretionary spending. While the company’s strategic investments and Bitcoin holdings provide optionality, the timing and amount of tax refunds and capital raises remain uncertain.
Bottom Line?
333D’s strong revenue growth and strategic AI investments position it well, but investors should watch how operating cash flows evolve as development costs normalise in FY2027.
Questions in the middle?
- How will the regulatory pathway for 333D’s AI clinical software progress under the Therapeutic Goods Administration?
- What impact will Firmus Grid’s capital raising and market performance have on the valuation of 333D’s minority stake?
- To what extent will Bitcoin market volatility influence 333D’s liquidity management and strategic asset allocation?